ImpactRX appoints Gregory Ellis CEO
This article was originally published in Scrip
ImpactRX, a provider of analytical models that demonstrate the impact of promotion on physician prescribing behaviour, has appointed Gregory Ellis president and chief executive officer. Mr Ellis joins ImpactRX from Rosetta, where he was a senior partner from 2002 to July 2011, helping the firm grow from $5 million to $240 million in annual revenue.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.